A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the efficacy and safety of three different
doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period
of 6 weeks in pediatric patients (aged 13-17 years) with schizophrenia